Eli Lilly Earnings Call Highlights Hyper-Growth Momentum

Eli Lilly And Company ((LLY)) has held its Q4 earnings call. Read on for the main highlights of the call.

Eli Lilly’s latest earnings call struck an upbeat tone as management highlighted exceptional revenue and earnings growth, surging demand for incretin-based obesity and diabetes drugs, and a deep, winning pipeline. Executives acknowledged mounting price pressure, heavier investment, and some access headwinds, but emphasized that volume growth and innovation should keep the growth story intact.

Record Revenue and EPS Underscore Breakout Year

Lilly reported full-year 2025 revenue of $65.2 billion, up 45% from 2024, underscoring the scale of demand for its new medicines. Earnings power expanded even faster, with EPS jumping 86% to $24.21, signaling strong operating leverage despite big investments in R&D and commercialization.

Q4 Performance Confirms Momentum

Fourth-quarter revenue climbed 43% year over year, while non-GAAP EPS reached $7.54, even after including sizable acquired R&D charges. The non-GAAP performance margin improved to 47.2%, up 4.2 percentage points, showing Lilly is managing costs while scaling rapidly.

Obesity and Diabetes Blockbusters Lead Growth

Key products generated more than $13 billion in Q4 revenue, rising 91% versus the prior year as obesity and diabetes therapies drove the surge. Zepbound more than doubled revenue and captured roughly 70% of new branded obesity prescriptions, while incretin analog prescriptions overall rose 33% in the U.S.

Franchise Market Leadership Broadens

Mounjaro expanded to more than 55% of new U.S. diabetes prescriptions, cementing its leadership in the category and fueling continued share gains. Beyond incretins, Kisanlo became the U.S. leader in amyloid-targeting therapies, while Omvo, Jayperca, and Verzenio all posted growth, particularly outside the U.S.

Deep Pipeline and Phase 3 Wins

Management spotlighted positive data from more than 25 Phase 3 trials and a total of 36 late-stage programs, showcasing an unusually broad growth engine. Key updates included full FDA approval and expanded use for pirtobrutinib, which showed large reductions in progression risk versus standard regimens in certain blood cancers.

Next-Generation Obesity Innovation Advances

Lilly is pushing beyond injectable incretins with orforglipron, an oral obesity therapy submitted in the U.S. and over 40 countries, and with the powerful retreutide program. TRIUMPH-4 data showed average weight loss of 29% and major reductions in pain scores, while orforglipron maintained weight in patients switching from other leading GLP-1 drugs.

Manufacturing Scale-Up Targets Massive Demand

To support explosive incretin demand, Lilly produced 1.8 times more doses in 2025 than in 2024 and brought new U.S. manufacturing sites online. Since 2020, the company has committed over $55 billion to global manufacturing, with further capacity planned in the U.S. and Europe to avoid supply constraints.

Balanced Capital Allocation Supports Growth and Returns

Even as Lilly invests heavily, it returned cash to shareholders with $1.3 billion in dividends and $1.5 billion in share repurchases during 2025. Management said these returns remain balanced against substantial R&D and commercial spending needed to sustain the company’s multi-year growth runway.

Commercial Reach and Access Agreements Expand

Lilly’s U.S. direct-to-patient platform engaged 1 million patients in 2025, reflecting a push to broaden access and education around its medicines. A new agreement with the U.S. government targets affordable out-of-pocket costs for obesity drugs within Medicare and Medicaid, supporting long-term volume growth even as it puts pressure on pricing.

Price Pressure Expected to Drag 2026 Growth

The company disclosed roughly a 7% U.S. price decline in Q4 and said pricing will be a low-to-mid-teens drag on 2026 revenue growth. Management tied this to government access deals, direct-to-patient pricing changes, and lower Medicaid prices, emphasizing that volume expansion should more than offset these headwinds over time.

Rising Operating Spend Weighs on Near-Term Margins

R&D spending grew 26% and marketing, selling, and administrative expenses rose 29% in 2025 as Lilly funds 36 Phase 3 programs and multiple launches. While this pressures near-term margins, the company maintained strong profitability and argues that today’s spending is essential to secure future growth.

Medicaid and Coverage Headwinds Near Term

Lilly expects reduced Medicaid access in 2026, including the loss of certain obesity coverage in states like California, which will hit reimbursed U.S. volumes. Management believes coverage could start recovering in 2027 as states reassess obesity treatment value, but the interim pressure adds to pricing and margin challenges.

Tolerability and Patient Selection Challenges Emerge

Retreutide’s impressive efficacy came with higher discontinuation rates for adverse events in lower-BMI participants, including patients stopping due to rapid or excessive weight loss. Lilly stressed the need for careful patient selection and tolerability management as these powerful medicines move into broader populations.

Late-Lifecycle Products Face Pressure

Several older products such as Trulicity, Talsa, and Verzenio are expected to be flat or decline as the focus shifts to next-generation therapies. In particular, Verzenio’s U.S. penetration appears to have plateaued, limiting its incremental growth contribution despite pockets of strength overseas.

Staggered International Launches for Oral Incretins

While orforglipron filings span more than 40 countries, management doesn’t expect most international launches until 2027, with only select markets coming later in 2026. That timeline means the high-potential oral obesity franchise will add limited ex-U.S. revenue in the near term, with a bigger impact in the back half of the decade.

Gross Margin Dynamics and Cost Offsets

Gross margin held steady at 83.2% in Q4, but Lilly guided for margins to remain stable to slightly lower as price concessions and new plant costs kick in. Management expects favorable product mix and productivity gains to offset much of the pressure, preserving what remains an elite profitability profile.

China NRDL Timing Distorts Quarterly Trends

The inclusion of Mounjaro on China’s national reimbursement list beginning January 2026 caused some purchasing to shift, creating noise in December 2025 sales. Lilly framed this as a timing issue rather than a demand concern, with reimbursement expected to support strong long-term uptake in that key market.

Guidance: Strong 2026 Growth Despite Headwinds

For 2026, Lilly guided revenue to $80–$83 billion, implying about 25% growth at the midpoint, and non-GAAP EPS of $33.50–$35.00 with margins in the mid-to-high 40s. The outlook assumes continued industry-leading volume growth, approval of orforglipron in the U.S., expanded obesity access in government programs, rising international reimbursement, and higher R&D and commercial spend that is outweighed by scaling demand.

Lilly’s earnings call painted a picture of a company in hyper-growth mode, powered by dominant obesity and diabetes drugs and an unusually rich late-stage pipeline. While investors must weigh meaningful price, access, and cost pressures, management’s confidence that volume and innovation will win out keeps the long-term equity story firmly bullish.